Overview

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

Status:
Completed

Trial end date:
2017-05-04

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Amgen
Onyx Therapeutics, Inc.

Treatments:

Carboplatin
Etoposide
Etoposide phosphate